Transcription factor CCAAT/enhancer-binding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 53, Issue 8, 2012, Pages 1577-1585

  Thoennissen, Nils H ^a   Thoennissen, Gabriela B ^a   Abbassi, Sam ^b   Nabavi Nouis, Shayan ^b   Sauer, Tim ^a   Doan, Ngan B ^c   Gery, Sigal ^b   Müller Tidow, Carsten ^a   Said, Jonathan W ^c   Koeffler, H Phillip ^b,d  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

circadian rhythm; mature B cell lymphoma; Transcription factor

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; MESSENGER RNA; SMALL INTERFERING RNA; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CIRCADIAN RHYTHM; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; FOLLICULAR LYMPHOMA; GENE ACTIVATION; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; PER2 GENE; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE; UPREGULATION;

APOPTOSIS; BIOPSY; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CIRCADIAN RHYTHM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MODELS, GENETIC; PERIOD CIRCADIAN PROTEINS;

EID: 84864223775     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.658792     Document Type: Article

References (37)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classifi cation of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008.
2. Clarke CA, Glaser SL. Changing incidence of non-Hodgkin lymphomas in the United States. Cancer 2002;94:2015-2023.
3. Mül ler AMS, Ihorst G, Mertelsmann R, et al. Epidemiology of non- Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005;84:1-12.
4. Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 2010;6:393-408.
5. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature 2002;418:935-941.
6. Schibler U, Sassone-Corsi P. A web of circadian pacemakers. Cell 2002;111:919-922.
7. L owrey PL, Takahashi JS. Mammalian circadian biology: elucidating genome-wide levels of temporal organization. Annu Rev Genomics Hum Genet 2004;5:407-441.
8. Griffi n EA Jr, Staknis D, Weitz CJ. Light-independent role of CRY1 and CRY2 in the mammalian circadian clock. Science 1999; 286:768-771.
9. Kume K, Zylka MJ, Sriram S, et al. mCRY1 and mCRY2 are essential components of the negative limb of the circadianclock feedback loop. Cell 1999;98:193-205.
10. Matsuo T, Yamaguchi S, Mitsui S, et al. Control mechanism of the circadian clock for timing of cell division in vivo. Science 2003;302: 255-259.
11. Fu L, Pelicano H, Liu J, et al. Th e circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002;111:41-50.
12. M ormont MC, Levi F. Circadian-system alterations during cancerprocesses: a review. Int J Cancer 1997;70:241-247.
13. Gery S, Gombart AF, Yi WS, et al. Transcription profi ling of C/EBP targets identifi es Per2 as a gene implicated in myeloid leukemia. Blood 2005;106:2827-2836.
14. Z hu Y, Leaderer D, Guss C, et al. Ala394Th r polymorphism in the clock gene NPAS2: a circadian modifi er for the risk of non-Hodgkin's lymphoma. Int J Cancer 2007;120:432-435.
15. L ahti TA, Partonen T, Kyyrönen P, et al. Night-time work predisposes to non-Hodgkin lymphoma. Int J Cancer 2008;123:2148-2151.
16. Micke O, Schäfer U, W örmann B, et al. Circadian variations of interleukin-2 receptors, serum thymidine kinase and beta- 2-microglobulin in patients with non-Hodgkin's lymphoma and normal controls. Anticancer Res 1997;17:3007-3010.
17. Th oennissen NH, Iwanski GB, Doan NB, et al. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative eff ects of gemcitabine on pancreatic cancer cells. Cancer Res 2009;69:5876-5884.
18. I wanski GB, Lee DH, En-Gal S, et al. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Br J Pharmacol 2010;160:998-1007.
19. G ery S, Komatsu N, Kawamata N, et al. Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer. Clin Cancer Res 2007;13:1399-1404.
20. M arks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009;107:600-608.
21. B otrugno OA, Santoro F, Minucci S. Histone deacetylase inhibitors as a new weapon in the arsenal of diff erentiation therapies of cancer. Cancer Lett 2009;280:134-144.
22. P anda S, Antoch MP, Miller BH, et al. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 2002;109: 307-320.
23. K ornmann B, Preitner N, Rifat D, et al. Analysis of circadian liver gene expression by ADDER, a highly sensitive method for the display of diff erentially expressed mRNAs. Nucleic Acids Res 2001;29:E51.
24. M endez-Ferrer S, Lucas D, Battista M, et al. Haematopoietic stem cell release is regulated by circadian oscillations. Nature 2008;452: 442-447.
25. C hen ST, Choo KB, Hou MF, et al. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 2005;26:1241-1246.
26. G ery S, Komatsu N, Baldjyan L, et al. Th e circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 2006;22:375-382.
27. G ery S, Virk R, Chumakov K, Yu A, Koeffl er HP. Th e clock gene Per2 links the circadian system to the estrogen receptor. Oncogene 2007;26:7916-7920.
28. Wood PA, Yang X, Hrushesky WJ. Clock genes and cancer. Integr Cancer Th er 2009;8:303-308.
29. Hoff Man Ae Zheng T, Ba Y, et al. Th e circadian gene NPAS2, putative tumor suppressor is involved in DNA damage response. Mol Cancer Res 2008;6 1461-1468
30. Y ang MY, Chang JG, Lin PM, et al. Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3. Cancer Sci 2006;97:1298-1307.
31. Mann BS, Johnson JR, Cohen MH, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007;12:1247-1250.
32. Kirschbaum M, Popplewell L, Nademanee A, et al. A phase 2 study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed or refractory indolent non-Hodgkin's lymphoma: a California Cancer Consortium study. Haematologica 2009;94(Suppl. 2): Abstract 166.
33. W ang H, Iakova P, Wilde M, et al. C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell 2001;8:817-828.
34. Porse BT, Pedersen TA, Hasemann MS, et al. Th e proline-histidinerich CDK2/CDK4 interaction region of C/EBPalpha is dispensable for C/EBPalpha-mediated growth regulation in vivo. Mol Cell Biol 2006;26:1028-1037.
35. Timchenko NA, Wilde M, Nakanishi M, et al. CCAAT/enhancerbinding protein alpha (C/EBP alpha) inhibits cell proliferation through the p21 (WAF-1/CIP-1/SDI-1) protein. Genes Dev 1996;10:804-815.
36. Pedersen TA, Kowenz-Leutz E, Leutz A, et al. Cooperation between C/EBP alpha TBP/TFIIB and SWI/SNF recruiting domains is required for adipocyte diff erentiation. Genes Dev 2001;15:3208-3216.
37. S lomiany BA, D'Arigo KL, Kelly MM, et al. C/EBP alpha inhibits cell growth via direct repression of E2F-DP-mediated transcription. Mol Cell Biol 2000;20:5986-5997.